PLGA-PEG Encapsulated sitamaquine nanoparticles drug delivery system against Leishmania donovani

Targeted drug delivery systems are a promising technology to increase the maximum mechanism of action with smaller dose of requirement, Therefore we have developed sitamaquine encapsulated PLGA-PEG nanoparticle (NP) attach with antibody to CD14 to target macrophage of infected tissues against leishmaniasis. The analyses of detailed structural characterization performed by transmission electron microscopy (TEM) and dynamic light scattering (DLS) confirmed the nano-size of the particle (size range of 20-30 nanometer scale) and fourier transform infrared spectroscopy (FTIR) for NP encapsulation confirmation. The ED50 value of sitamaquine showing less than sitamaquine antileishmanial drug alone and three fold decrease of macrophage infection in which hamster treated with PLGA-PEG encapsulated sitamaquine (0.0039 ± 0.0012 )as compare to hamster treated alone with sodium sitamaquine (0.0123 ± 0.0047). Further significantly inhibition of amastigotes in the splenic tissue with PLGA-PEG encapsulated sitamaquine was significantly more than with conventional (89.01±6 verse 71.39 ±12).